Abaxis (NASDAQ: ABAX) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Abaxis and GenMark Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abaxis 1 3 1 0 2.00
GenMark Diagnostics 0 1 5 0 2.83

Abaxis presently has a consensus price target of $47.63, indicating a potential upside of 0.64%. GenMark Diagnostics has a consensus price target of $11.80, indicating a potential upside of 168.18%. Given GenMark Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe GenMark Diagnostics is more favorable than Abaxis.

Valuation and Earnings

This table compares Abaxis and GenMark Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abaxis $227.22 million 4.73 $32.71 million $1.20 39.43
GenMark Diagnostics $49.27 million 4.89 -$50.60 million ($1.22) -3.61

Abaxis has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Abaxis, indicating that it is currently the more affordable of the two stocks.

Dividends

Abaxis pays an annual dividend of $0.64 per share and has a dividend yield of 1.4%. GenMark Diagnostics does not pay a dividend. Abaxis pays out 53.3% of its earnings in the form of a dividend.

Institutional & Insider Ownership

97.7% of Abaxis shares are held by institutional investors. 4.3% of Abaxis shares are held by insiders. Comparatively, 7.5% of GenMark Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Abaxis has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Abaxis and GenMark Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abaxis 11.98% 10.18% 8.84%
GenMark Diagnostics -116.76% -100.33% -57.22%

Summary

Abaxis beats GenMark Diagnostics on 9 of the 15 factors compared between the two stocks.

Abaxis Company Profile

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.